Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis

Phase 3

Completed

Conditions: Myasthenia Gravis, Generalized

Interventions: Drug: zilucoplan (RA101495)
Drug: Placebo

Registration Number: NCT04115293

Lead Sponsor: Ra Pharmaceuticals, Inc.

Brief Summary: The RAISE study is a multicenter, randomized, double-blind, placebo controlled study to confirm the efficacy, safety, and tolerability of zilucoplan in subjects with generalized Myasthenia Gravis. Subjects will be randomized in a 1:1 ratio to receive daily SC doses of 0.3 mg/kg zilucoplan or placebo for 12 weeks.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 174

Inclusion Criteria

Diagnosis of gMG [Myasthenia Gravis Foundation of America (MGFA) Class II-IV] at Screening
Positive serology for acetylcholine receptor (AChR) autoantibodies
MG-ADL Score of ≥ 6 at Screening and Baseline
QMG score ≥ 12 at Screening and Baseline
No change in corticosteroid dose for at least 30 days prior to Baseline or anticipated to occur during the 12-week Treatment Period
No change in immunosuppressive therapy, including dose, for at least 30 days prior to Baseline or anticipated to occur during the 12-week Treatment Period

Exclusion Criteria

Thymectomy within 12 months prior to Baseline or scheduled to occur during the 12 week Treatment Period
History of meningococcal disease
Current or recent systemic infection within 2 weeks prior to Baseline or injection requiring intravenous (IV) antibiotics within 4 weeks prior to Baseline

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
0.3 mg/kg zilucoplan (RA101495)	zilucoplan (RA101495)	-
Placebo	Placebo	-

Primary Outcome Measures

Name	Time	Method
Change From Baseline (CFB) to Week 12 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score	From Baseline to End of Treatment (Week 12)	The MG-ADL is an 8-item patient-reported outcome measure assessing MG symptoms and their effects on daily activities. Each item in the scale scored 0 to 3 (0=None, 3=severe disease) point scale. The total score was the sum of all individual item scores and ranged from 0 to 24. Higher scores indicated more severe disability due to MG. A decrease from Baseline score indicated improvement.

Secondary Outcome Measures

Name	Time	Method
Change From Baseline to Week 12 in the Quantitative Myasthenia Gravis (QMG) Total Score	From Baseline to End of Treatment (Week 12)	The QMG is a standardized and validated quantitative strength scoring system that was developed specifically for MG. The scale consisted of 13 items. Each item in the scale scored on a 0 to 3-point scale, ranging from 0 (no weakness) to 3 (severe weakness), summing up to the overall score range from 0 to 39. Higher scores indicated more severe impairment. A decrease from Baseline score indicated improvement.
Change From Baseline to Week 12 in the Myasthenia Gravis - Quality of Life Revised (MG-QoL15r) Scale Total Score	From Baseline to End of Treatment (Week 12)	The MG-QoL15r is a 15-item patient-reported outcome measure designed to assess quality of life in patients with MG. Each item in the scale scored on a 0 to 2-point scale (0=Not much at all, 1=Somewhat, 2=Very much). The total score was the sum of the 15 individual item scores, ranging from 0 to 30. Higher scores indicated more severe impact of the disease on aspects of the patient's life. A decrease from Baseline score indicated improvement.
Time to First Receipt of Rescue Therapy Over the 12-week Treatment Period	From Baseline to End of Treatment (Week 12)	Time to first receipt of rescue therapy over the 12-week treatment period (in days) was defined as the date of first rescue therapy use minus date of first Investigational Medicinal Product (IMP) + 1.
Change From Baseline to Week 12 in the Myasthenia Gravis Composite (MGC) Scale Total Score	From Baseline to End of Treatment (Week 12)	The total MGC score was sum of responses to 10 individual items : 1. Ptosis upward gaze (0 to 3), 2. Double vision on lateral gaze, left or right (0, to 4), 3. Eye closure (0 to 2), 4. Talking (0 to 6), 5. Chewing (0 to 6), 6. Swallowing \[0 to 6\], 7. Breathing (0 to 9), 8. Neck flexion or extension (0 to 4), 9. Shoulder abduction (0 to 5), 10. Hip flexion (0 to 5). The higher score for each item indicated severity. The total score ranged 0 to 50 with higher score indicative of severe disease activity). A decrease from Baseline score showed improvement.
Percentage of Participants Achieving Minimal Symptom Expression (MSE) at Week 12 Without Rescue Therapy	End of Treatment (Week 12)	Percentage of Participants achieving MSE was defined as achieving a MG-ADL value of a 0 (No MG symptoms) or 1 (Mild MG symptoms) at Week 12 and not having taken rescue therapy. Any participant with an event of death, myasthenic crisis or rescue therapy was considered as non-responders. Any other missing data was imputed using the missing at Random (MAR) assumption.
Percentage of Participants Achieving a ≥ 3-point Reduction in MG-ADL Score at Week 12 Without Rescue Therapy	End of Treatment (Week 12)	Percentage of participants achieving a ≥ 3-point reduction in MG-ADL Score at Week 12 without rescue therapy were reported. The MG-ADL is an 8-item patient-reported outcome measure assessing MG symptoms and their effects on daily activities. Each item in the scale scored on a 0 to 3 (0=None, 3=severe disease) point scale. The total score was the sum of all individual item scores and ranged from 0 to 24. Higher scores indicated more severe disability due to MG. Any participant with an event of death, myasthenic crisis or rescue therapy was considered as non-responders. Any other missing data was imputed using the MAR assumption.
Percentage of Participants Achieving a ≥5-point Reduction in QMG Score Without Rescue Therapy at Week 12	End of Treatment (Week 12)	Percentage of participants achieving a ≥5-point reduction in QMG Score without rescue therapy at Week 12 were reported. The QMG is a standardized and validated quantitative strength scoring system that was developed specifically for MG. The scale consisted of 13 items. Each item in the scale scored on a 0 to 3-point scale, ranging from 0 (no weakness) to 3 (severe weakness), summing up to the overall score range from 0 to 39. Higher scores indicated more severe impairment. Any participant with an event of death, myasthenic crisis or rescue therapy was considered as non-responders. Any other missing data was imputed using the MAR assumption.
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)	From Baseline (Day 1) to Safety Follow-up visit (19 Weeks [12 weeks Treatment Period plus up to 7 weeks Follow-up])	A TEAE is defined as an AE starting on or after the time of first administration of IMP and up to and including 40 days after the final dose (or last contact depending on which occurs first). Adverse events starting before the date of the first administration of IMP were not considered TEAEs.

Trial Locations

Locations (77): Site 41: Diagnostic and Medical Clinic
🇺🇸
Mobile, Alabama, United States
Site 116: Neuromuscular Clinic and Research Center
🇺🇸
Phoenix, Arizona, United States
Site 4: University of Southern California
🇺🇸
Los Angeles, California, United States
Site 31: University of California Irvine
🇺🇸
Orange, California, United States
Site 220: Investigator Site
🇺🇸
Pasadena, California, United States
Site 160: Forbes Norris MDA/ALS Research and Treatment Center
🇺🇸
San Francisco, California, United States
Site 24: Yale University
🇺🇸
New Haven, Connecticut, United States
Site 27: George Washington University
🇺🇸
Washington, District of Columbia, United States
Site 182: Gelasio Baras Neurology
🇺🇸
Miami, Florida, United States
Site 25: University of South Florida
🇺🇸
Tampa, Florida, United States
Scroll for more (67 remaining)
Site 41: Diagnostic and Medical Clinic
🇺🇸Mobile, Alabama, United States